Altimmune
ALT

$6.75

0.61%

Market Cap: 479M

About: Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Employees: 59

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 7 analysts

0

News positive %

of 93 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

81% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 31

77% more call options, than puts

Call options by funds: $20.6M | Put options by funds: $11.6M

29% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 38

20.13% more ownership

Funds ownership: 62.36% [Q4 2023] → 82.49% (+20.13%) [Q1 2024]

20% more capital invested

Capital invested by funds: $377M [Q4 2023] → $451M (+$74.2M) [Q1 2024]

18% more funds holding

Funds holding: 141 [Q4 2023] → 166 (+25) [Q1 2024]

0% more funds holding in top 10

Funds holding in top 10: 4 [Q4 2023] → 4 (+0) [Q1 2024]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$12

78%

upside

Avg. target

$19

181%

upside

High target

$25

270%

upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

B. Riley Securities Mayank Mamtani	196%upside $20	Buy Reiterated	25 Jun 2024
Piper Sandler Yasmeen Rahimi	270%upside $25	Overweight Maintained	21 Jun 2024
HC Wainwright & Co. Patrick Trucchio	78%upside $12	Buy Reiterated	14 May 2024
JMP Securities Jonathan Wolleben	256%upside $24	Market Outperform Maintained	10 May 2024
HC Wainwright & Co. Patrick Trucchio	78%upside $12	Buy Maintained	1 Apr 2024

See Analyst Rankings

Financial journalist opinion

Based on 93 articles about ALT published over the past 30 days

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

Weekly subcutaneous doses of pemvidutide resulted in up to 68.5% relative reduction in liver fat content (LFC), with up to 55.6% of subjects achieving LFC normalization after 12 weeks of treatment

Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology

The Motley Fool

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?

Eli Lilly and Novo Nordisk will need to share the weight-loss drugs market someday. Altimmune's candidate looks like it could succeed where their medicines struggle.

Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs?

3 Undervalued Biotech Stocks With Breakout Potential

Undervalued biotech stocks will always be relevant for the savvy investor. The biotech world is evolving rapidly, with pharmaceutical giants tirelessly building on their pipelines and technologies.

3 Undervalued Biotech Stocks With Breakout Potential

Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio

Tired of watching your portfolio crawl along? Standard investment advice often includes diversifying into bland, safe bets.

Forget Boring Diversification! 3 Wild-Card Stocks to Spice Up Your Portfolio

The Motley Fool

Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics

GLP-1 medicines for obesity are all the rage these days. Viking Therapeutics' candidate has the edge in the speed of weight loss.

Better GLP-1 Biotech Stock: Altimmune vs. Viking Therapeutics

7 Bullish Stock Picks With the Potential to Turn $5K Into $50K

Investors looking for opportunities will always be interested in high-potential stocks capable of turning $5K into $50K. Realistically speaking, securing 10x returns is not particularly easy.

7 Bullish Stock Picks With the Potential to Turn $5K Into $50K

The 7 Best Under $10 Stocks to Buy in July 2024

Savvy investors are discovering rewarding opportunities in some of the best stocks under $10 a share. Years ago, I found Advanced Micro Devices (NASDAQ: AMD ) at $10 a share and watched it rocket above $200 on the artificial intelligence (AI) boom.

The 7 Best Under $10 Stocks to Buy in July 2024

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89388&wire=1 or contact Joseph E. Levi, Esq.

Altimmune, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form?prid=89367&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024 - ALT

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ:ALT) and certain officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 24-cv-01315, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Altimmune securities between December 1, 2023 and April 26, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT

See News Rankings